Autobahn Labs Partnership
About the Program:
Autobahn Labs LLC is a newly conceived drug discovery and development engine funded by Samsara BioCapital, Evotec, and KCK Group. Their goal is to catalyze the translation of nascent academic projects from partner institutions into transformational medicines. These programs, often too embryonic to attract conventional life sciences venture capital, will be shepherded by a team of experienced drug developers, in conjunction with an R&D partner Evotec, a world leading CRO.
Autobahn commits up to $5 million in funding and provides the necessary research and development to transform therapeutic projects, or compelling ideas, into validated preclinical drug candidates. A partnership with Autobahn includes access to Evotec's high throughput drug screening and discovery platforms, drug optimization and validation, as well as basic research and preclinical work with cell lines, primary human cells, iPSCs, and animal models. Projects can span various drug modalities including small molecules, antibodies and other biologics, gene, and cell therapy. All work is done in close collaboration with the academic founders who are expected to be intimately involved throughout the drug development process.
What makes Autobahn unique?
First, as an investor and partner, Evotec provides their extensive drug discovery and development expertise. Second, Autobahn’s investor base has a long-term view of investing so we can remain involved in a project with our partner universities and faculty for years. Third, we take promising science and generate actionable data in the most capital-efficient way possible.
Autobahn and OIC are working together to increase access to data resources, funding, and scientific partners who can support the advancement of technologies from UC San Diego. Ultimately, the goal is specifically to pair industry members with UC San Diego scientists and researchers to identify potential research projects of mutual interest. By working together, we can pool resources, funding, and our robust networks of partners and investors to assist more teams and startups than ever before.